Erick Wayne DeVinney - 15 Feb 2022 Form 4 Insider Report for Axogen, Inc. (AXGN)

Reporting relationship: VP Peripheral Nerve Science
Issuer ticker: AXGN
Reported as of: 15 Feb 2022
Net transaction value: -$3,006
SEC form: 4
Accepted by SEC: 17 Feb 2022, 15:05:31 UTC
Prior SEC filing: 29 Dec 2021
Next SEC filing: 18 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/Erick DeVinney

Key filing fact

Erick Wayne DeVinney filed Form 4 for Axogen, Inc. (AXGN) on 17 Feb 2022.

Key facts

This page summarizes Erick Wayne DeVinney's Form 4 filing for Axogen, Inc. (AXGN).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 17 Feb 2022, 15:05.

Change

Previous filing in this sequence was filed on 29 Dec 2021.
Current net transaction value: -$3,006.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AXGN transaction

Common Stock

Award

Transaction value: $0
Shares: +1,181
Change %: +1.4%
Price: $0.000000
Shares after: 88,432
Date: 15 Feb 2022
Ownership: Direct
Footnotes: F1, F2

AXGN transaction

Common Stock

Tax liability

Transaction value: $3,006
Shares: -357
Change %: -0.4%
Price: $8.42
Shares after: 88,075
Date: 15 Feb 2022
Ownership: Direct
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

This reflects the number of shares that became vested as of February 15, 2022 upon the attainment of certain performance criteria.

Footnote F2

Includes 2 shares acquired under the Axogen stock purchase plan on December 31, 2021.

Footnote F3

The reported shares were sold, in compliance with company policy as to delivery of compensation based equity, with proceeds from such being used to cover the Reporting Person's tax withholding liability in connection with a portion of a performance stock award that vested on February 15, 2022.